TCR2 Therapeutics Analyst Ratings
TCR2 Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/06/2023 | 817.43% | Piper Sandler | $8 → $10 | Maintains | Overweight |
| 01/05/2023 | 83.49% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 11/21/2022 | 1092.66% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 11/08/2022 | 83.49% | SVB Leerink | $3 → $2 | Maintains | Market Perform |
| 05/19/2022 | 1184.4% | HC Wainwright & Co. | $19 → $14 | Maintains | Buy |
| 03/23/2022 | 175.23% | SVB Leerink | $7 → $3 | Maintains | Market Perform |
| 01/19/2022 | 358.72% | Goldman Sachs | $28 → $5 | Downgrades | Buy → Neutral |
| 01/13/2022 | 1643.12% | HC Wainwright & Co. | $25 → $19 | Maintains | Buy |
| 11/10/2021 | 542.2% | SVB Leerink | $8 → $7 | Maintains | Market Perform |
| 10/21/2021 | 633.94% | SVB Leerink | $18 → $8 | Downgrades | Outperform → Market Perform |
| 09/20/2021 | 2560.55% | Truist Securities | $40 → $29 | Maintains | Buy |
| 09/20/2021 | 2193.58% | HC Wainwright & Co. | $37 → $25 | Maintains | Buy |
| 09/17/2021 | 909.17% | Wedbush | $45 → $11 | Downgrades | Outperform → Neutral |
| 08/06/2021 | 2744.04% | SVB Leerink | $34 → $31 | Maintains | Outperform |
| 06/24/2021 | 2652.29% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 03/11/2021 | 3019.27% | SVB Leerink | $41 → $34 | Maintains | Outperform |
| 12/14/2020 | 3294.5% | HC Wainwright & Co. | $32 → $37 | Maintains | Buy |
| 11/30/2020 | 3386.24% | Roth Capital | $35 → $38 | Maintains | Buy |
| 08/21/2020 | — | Mizuho | Initiates Coverage On | → Buy | |
| 08/13/2020 | 3569.72% | Truist Securities | → $40 | Initiates Coverage On | → Buy |
| 08/13/2020 | 2835.78% | HC Wainwright & Co. | $33 → $32 | Maintains | Buy |
| 08/12/2020 | 2193.58% | SVB Leerink | $26 → $25 | Maintains | Outperform |
| 08/12/2020 | 3111.01% | Piper Sandler | → $35 | Initiates Coverage On | → Overweight |
| 07/27/2020 | 3111.01% | Roth Capital | $16 → $35 | Upgrades | Neutral → Buy |
| 07/27/2020 | 2927.52% | HC Wainwright & Co. | $19 → $33 | Maintains | Buy |
| 11/04/2019 | 1643.12% | HC Wainwright & Co. | → $19 | Initiates Coverage On | → Buy |
| 05/31/2019 | 1367.89% | Roth Capital | → $16 | Initiates Coverage On | → Neutral |
| 03/11/2019 | 2468.81% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 3294.5% | BMO Capital | → $37 | Initiates Coverage On | → Outperform |
| 03/11/2019 | 2744.04% | Jefferies | → $31 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 01/06/2023 | 817.43% | 派珀·桑德勒 | $8 → $10 | 维护 | 超重 |
| 01/05/2023 | 83.49% | EF Hutton | → $2 | 开始承保 | →保留 |
| 11/21/2022 | 1092.66% | HC Wainwright公司 | $14 → $13 | 维护 | 买 |
| 11/08/2022 | 83.49% | SVB Leerink | $3 → $2 | 维护 | 市场表现 |
| 05/19/2022 | 1184.4% | HC Wainwright公司 | $19 → $14 | 维护 | 买 |
| 03/23/2022 | 175.23% | SVB Leerink | $7 → $3 | 维护 | 市场表现 |
| 01/19/2022 | 358.72% | 高盛 | $28 → $5 | 评级下调 | 购买→中性 |
| 01/13/2022 | 1643.12% | HC Wainwright公司 | $25 → $19 | 维护 | 买 |
| 11/10/2021 | 542.2% | SVB Leerink | $8 → $7 | 维护 | 市场表现 |
| 10/21/2021 | 633.94% | SVB Leerink | $18 → $8 | 评级下调 | 跑赢→市场表现 |
| 09/20/2021 | 2560.55% | Truist证券 | $40 → $29 | 维护 | 买 |
| 09/20/2021 | 2193.58% | HC Wainwright公司 | $37 → $25 | 维护 | 买 |
| 09/17/2021 | 909.17% | 韦德布什 | $45 → $11 | 评级下调 | 跑赢→中性 |
| 08/06/2021 | 2744.04% | SVB Leerink | $34 → $31 | 维护 | 跑赢大盘 |
| 06/24/2021 | 2652.29% | 高盛 | → $30 | 开始承保 | →购买 |
| 03/11/2021 | 3019.27% | SVB Leerink | $41 → $34 | 维护 | 跑赢大盘 |
| 12/14/2020 | 3294.5% | HC Wainwright公司 | $32 → $37 | 维护 | 买 |
| 11/30/2020 | 3386.24% | 罗斯资本 | $35 → $38 | 维护 | 买 |
| 08/21/2020 | — | 瑞穗 | 开始承保 | →购买 | |
| 08/13/2020 | 3569.72% | Truist证券 | → $40 | 开始承保 | →购买 |
| 08/13/2020 | 2835.78% | HC Wainwright公司 | $33 → $32 | 维护 | 买 |
| 08/12/2020 | 2193.58% | SVB Leerink | $26 → $25 | 维护 | 跑赢大盘 |
| 08/12/2020 | 3111.01% | 派珀·桑德勒 | → $35 | 开始承保 | →超重 |
| 07/27/2020 | 3111.01% | 罗斯资本 | $16 → $35 | 升级 | 中性→购买 |
| 07/27/2020 | 2927.52% | HC Wainwright公司 | $19 → $33 | 维护 | 买 |
| 11/04/2019 | 1643.12% | HC Wainwright公司 | → $19 | 开始承保 | →购买 |
| 05/31/2019 | 1367.89% | 罗斯资本 | → $16 | 开始承保 | →中性 |
| 03/11/2019 | 2468.81% | 韦德布什 | → $28 | 开始承保 | →跑赢大盘 |
| 03/11/2019 | 3294.5% | 蒙特利尔银行资本 | → $37 | 开始承保 | →跑赢大盘 |
| 03/11/2019 | 2744.04% | 杰富瑞 | → $31 | 开始承保 | →购买 |
What is the target price for TCR2 Therapeutics (TCRR)?
TCR2治疗(TCRR)的目标价格是多少？
The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by Piper Sandler on January 6, 2023. The analyst firm set a price target for $10.00 expecting TCRR to rise to within 12 months (a possible 817.43% upside). 8 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年1月6日报道了TCR2治疗公司(纳斯达克：TCRR)的最新目标价。这家分析公司将目标价定为10美元，预计TCRR将在12个月内升至(可能上涨817.43%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for TCR2 Therapeutics (TCRR)?
TCR2治疗公司(TCRR)的最新分析师评级是什么？
The latest analyst rating for TCR2 Therapeutics (NASDAQ: TCRR) was provided by Piper Sandler, and TCR2 Therapeutics maintained their overweight rating.
派珀·桑德勒提供了对TCR2治疗公司(纳斯达克代码：TCRR)的最新分析师评级，TCR2治疗公司维持其增持评级。
When is the next analyst rating going to be posted or updated for TCR2 Therapeutics (TCRR)?
TCR2治疗公司(TCRR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TCR2 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TCR2 Therapeutics was filed on January 6, 2023 so you should expect the next rating to be made available sometime around January 6, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与TCR2治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。TCR2治疗公司的上一次评级是在2023年1月6日提交的，因此您应该预计下一次评级将在2024年1月6日左右提供。
Is the Analyst Rating TCR2 Therapeutics (TCRR) correct?
分析师对TCR2治疗公司(TCRR)的评级正确吗？
While ratings are subjective and will change, the latest TCR2 Therapeutics (TCRR) rating was a maintained with a price target of $8.00 to $10.00. The current price TCR2 Therapeutics (TCRR) is trading at is $1.09, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的TCR2治疗(TCRR)评级保持不变，目标价在8.00美元至10.00美元之间。目前TCR2治疗公司(TCRR)的交易价格为1.09美元，超出了分析师的预测范围。